These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 3127916)
1. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Mannucci PM; Vicente V; Alberca I; Sacchi E; Longo G; Harris AS; Lindquist A Thromb Haemost; 1987 Dec; 58(4):1037-9. PubMed ID: 3127916 [TBL] [Abstract][Full Text] [Related]
2. Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies. Ghirardini A; Mariani G; Iacopino G; Tirindelli MC; Solinas S; Moretti T Thromb Haemost; 1987 Oct; 58(3):896-8. PubMed ID: 3124287 [TBL] [Abstract][Full Text] [Related]
3. Comparison between subcutaneous and intravenous DDAVP in mild and moderate hemophilia A. De Sio L; Mariani G; Muzzucconi MG; Chistolini A; Tirindelli MC; Mandelli F Thromb Haemost; 1985 Aug; 54(2):387-9. PubMed ID: 3936212 [TBL] [Abstract][Full Text] [Related]
4. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Lethagen S; Harris AS; Sjörin E; Nilsson IM Thromb Haemost; 1987 Dec; 58(4):1033-6. PubMed ID: 3127915 [TBL] [Abstract][Full Text] [Related]
5. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP). Köhler M; Hellstern P; Miyashita C; von Blohn G; Wenzel E Thromb Haemost; 1986 Feb; 55(1):108-11. PubMed ID: 3085261 [TBL] [Abstract][Full Text] [Related]
6. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease. White B; Lawler P; Riddell A; Nitu-Whalley IC; Hermans C; Lee CA; Brown SA Br J Haematol; 2004 Jul; 126(1):100-4. PubMed ID: 15198739 [TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects. MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807 [TBL] [Abstract][Full Text] [Related]
8. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis]. Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813 [TBL] [Abstract][Full Text] [Related]
9. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII). Garcia VV; Silva IA; Borrasca AL Thromb Haemost; 1982 Aug; 48(1):91-3. PubMed ID: 6813999 [TBL] [Abstract][Full Text] [Related]
10. The clinical significance of different routes of desmopressin (DDAVP) administration in various bleeding disorders. Mörsdorf S; Köhler M; Leipnitz G; Wenzel E Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):503-7. PubMed ID: 2465962 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease. Gill JC; Ottum M; Schwartz B J Pediatr; 2002 May; 140(5):595-9. PubMed ID: 12032528 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and haematological effects of desmopressin. Köhler M; Harris A Eur J Clin Pharmacol; 1988; 35(3):281-5. PubMed ID: 3141199 [TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy of desmopressin in the treatment of mild hemophilia A in children]. Bai ST; Lu J; Sheng GY; Xu ST; Xie L; Peng S Zhongguo Dang Dai Er Ke Za Zhi; 2011 Sep; 13(9):715-7. PubMed ID: 21924018 [TBL] [Abstract][Full Text] [Related]
14. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Deitcher SR; Tuller J; Johnson JA Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955 [TBL] [Abstract][Full Text] [Related]
15. [Current clinical aspects in hemophilia treatment]. Meili EO Schweiz Med Wochenschr; 1989 Sep; 119(39):1332-41. PubMed ID: 2508219 [TBL] [Abstract][Full Text] [Related]
16. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Rittig S; Jensen AR; Jensen KT; Pedersen EB Clin Endocrinol (Oxf); 1998 Feb; 48(2):235-41. PubMed ID: 9579238 [TBL] [Abstract][Full Text] [Related]
17. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease. Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368 [TBL] [Abstract][Full Text] [Related]
18. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235 [TBL] [Abstract][Full Text] [Related]
19. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion. Casonato A; Pontara E; Boscaro M; Dannhauser D; Sartori MT; Girolami A Haematologia (Budap); 1993; 25(1):57-67. PubMed ID: 8339998 [TBL] [Abstract][Full Text] [Related]
20. [Subcutaneous administration of desmopressin to plasma donors: a controlled study]. Palacios S; Zuazu I; Candela MJ; Rivera J; Vicente V Med Clin (Barc); 1995 Oct; 105(14):525-7. PubMed ID: 8523926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]